Skin bacterial infections – always a topical problem

Bacterial skin infections are one of the most common reasons for visiting a dermatologist. A huge number of different microor-ganisms live on the human skin, but sometimes due to some external and internal factors the balance is disturbed, which leads to the predominance of one or more colonies and the subsequent development of the infection. Often staphylococci or streptococci are the cause of pyodermias (this is how skin bacterial infections are usually called). In the treatment of pyodermias, local antibacterial drugs are most often used. But given the free access to antibiotics and their thoughtless use, the sensitivity of many strains of microorganisms to the effects of drugs is reduced, which in many cases makes treatment difficult. According to various data, the sensitivity to fusidic acid remains very high, which makes fusidic acid-based drugs an optimal choice for therapy of bacterial infections. It is worth noting that recent studies have also demonstrated the anti-inflammatory activity of fusidic acid, which has a positive effect on the effectiveness of therapy. In today’s realities, the problem of bacterial skin infections remains as urgent as ever. Prolonged use of personal protective equipment and, in particular, medical masks creates ideal conditions for increased growth of opportunistic microorganisms. In this article, we present a case from our own practice. Impetigo developed in a patient after improper use of personal protective equipment. Fusidic acid topical therapy achieved a good clinical result after only 7 days. Thus, given the prevalence of pyodermias, fusidic acid-based drugs may be the optimal solution to the problem.

1. Grice E.A., Kong H.H., Conlan S., Deming C.B., Davis J., Young A.C. et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190–1192. doi: 10.1126/science.1171700.

2. Gao Z., Tseng C.H., Pei Z., Blaser M.J. Molecular analysis of human forearm superficial skin bacterial biota. Proc Natl Acad Sci USA. 2007;104(8): 2927–2932. doi: 10.1073/pnas.0607077104.

3. Gao Z., Tseng C.H., Strober B.E., Pei Z., Blaser M.J. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. PLoS One. 2008;3(7):e2719. doi: 10.1371/journal.pone.0002719.

4. Blaser M.J., Dominguez-Bello M.G., Contreras M., Magris M., Hidalgo G., Estrada I. et al. Distinct cutaneous bacterial assemblages in a sampling of South American Amerindians and US residents. ISME J. 2013;7(1):85–95. doi: 10.1038/ismej.2012.81.

5. Stulberg D.L., Penrod M.A., Blatny R.A. Common bacterial skin infections. Am Fam Physician. 2002;66(1):119–24. Available at: https://pubmed.ncbi.nlm.nih.gov/12126026.

6. Sergeev A.Y., Burtseva G.N., Sergeeva M.A. Evolving concepts and emerging solutions to the problem of staphylococcal infection in dermatology. Immunopatologiya, allergologiya, infektologiya = Immunopathology, Allergology, Infectology. 2019;(3):48–62. (In Russ.) doi: 10.14427/jipai.2019.3.48.

7. Williamson D.A., Carter G.P., Howden BP. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. Clin Microbiol Rev. 2017;30(3):827–860. doi: 10.1128/CMR.00112-16.

8. Farrell D.J., Mendes R.E., Castanheira M., Jones R.N. Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in US Medical Centers in 2014. Antimicrob Agents Chemother. 2016;60(6):3827–3831. doi: 10.1128/AAC.00238-16.

9. Pourakbari B., Mahmoudi S., Moradzadeh M., Mahzari M., Ashtiani M.T.H., Tanzifi P., Mamishi S. Antimicrobial Resistance Patterns of the Gram-positive Bacteria Isolated from Children with Bloodstream Infection in an Iranian Referral Hospital: A 6-year Study. Infect Disord Drug Targets. 2018;18(2):136–144. doi: 10.2174/1871526517666170821164343.

10. Williamson D.A., Carter G.P., Howden B.P. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns. Clin Microbiol Rev. 2017;30(3):827–860. doi: 10.1128/CMR.00112-16.

11. Stuttgen G., Bauer E. Penetration and permeation into human skin of fusidic acid in different galenical formulations. Arzneimittelforschung. 1988;38(5): 730–735. Available at: https://pubmed.ncbi.nlm.nih.gov/3415719.

12. Wu P.P., He H., Hong W.D., Wu T.R., Huang G.Y., Zhong Y.Y. et al. The biological evaluation of fusidic acid and its hydrogenation derivative as antimicrobial and anti-inflammatory agents. Infect Drug Resist. 2018;11:1945–1957. doi: 10.2147/IDR.S176390.